TriangleNCT04844073 · OUTCOME
Dose Escalation Phase: Recommended Phase 2 Dose (RP2D) of TAK-186
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- mcg per kg
- Interval / dispersion
- Not reported
- Time frame
- Up to 19 months
What was measured
RP2D, the maximum tolerated dose (MTD) of TAK-186 was determined.
Analysis population: Safety population included all participants who received at least 1 dose of TAK-186.
Groups in this outcome
Dose Escalation Phase
Participants received sequential doses of TAK-186 as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death.
| Group | Source count |
|---|---|
| Dose Escalation Phase | 64 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dose Escalation Phase | 10 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 10
- denoms
- counts
- group Id
- OG000
- value
- 64
- units
- Participants
- description
- RP2D, the maximum tolerated dose (MTD) of TAK-186 was determined.
- groups
- description
- Participants received sequential doses of TAK-186 as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death.
- id
- OG000
- title
- Dose Escalation Phase
- param Type
- NUMBER
- population Description
- Safety population included all participants who received at least 1 dose of TAK-186.
- reporting Status
- POSTED
- time Frame
- Up to 19 months
- title
- Dose Escalation Phase: Recommended Phase 2 Dose (RP2D) of TAK-186
- type
- SECONDARY
- unit Of Measure
- mcg per kg
Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0
Preserved source evidence · Not medical advice